Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis
The product is expected to be launched in December 2023
Furthering cell therapy ambition across oncology and autoimmune diseases
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated
